This study reveals that inhaled xenon induces microglia into a protective intermediate activation state (pre-MGnD), enhancing Aβ plaque compaction, reducing neuritic dystrophy, and exerting anti-inflammatory and neuroprotective effects via the IFNγ signaling pathway, highlighting its potential therapeutic value in Alzheimer's disease.
Literature Overview
This paper, 'Inhaled Xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy,' published in Science Translational Medicine, reviews and summarizes the regulatory effects of xenon (Xe)—an inert gas—on microglial function and its impact on Aβ and tau pathologies in mouse models of Alzheimer's disease (AD). Using multiple transgenic mouse models combined with single-cell RNA sequencing, behavioral testing, and pathological analyses, the study systematically demonstrates that Xe inhalation drives microglia into an intermediate activation state (pre-MGnD), enhancing phagocytic activity, suppressing neuroinflammation, and improving disease-related phenotypes. This work provides a novel intervention strategy for targeting the neuroimmune system in AD therapy.Background Knowledge
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized primarily by β-amyloid (Aβ) plaque deposition and neurofibrillary tangles formed by hyperphosphorylated tau protein. In recent years, microglia—the resident immune cells of the central nervous system—have gained increasing attention for their role in AD pathogenesis. In disease states, microglia transition from a homeostatic state to disease-associated microglia (DAM or MGnD), a process associated with increased inflammatory cytokine release, dysfunctional phagocytosis, and elevated oxidative stress, all of which exacerbate neurodegeneration. Although genome-wide association studies (GWAS) have identified microglia as a key cell type in late-onset AD genetic risk, no effective microglia-targeted therapies have yet reached clinical application.
Xenon is a clinically used inert gas with excellent blood-brain barrier permeability and has demonstrated neuroprotective effects in models of brain injury. Its primary mechanism is believed to involve NMDA receptor antagonism, but its effects on chronic neurodegenerative diseases, particularly neuroimmune regulation in AD, have not been systematically studied. This study addresses this gap by investigating whether Xe can modulate AD pathology by altering microglial phenotypes. The research employs various mouse models including APP/PS1, 5xFAD (Aβ deposition models), P301S tau (tauopathy model), and humanized 5x-MITRG mice, along with genetic tools such as Clec7a-CreERT2 and Cx3cr1-CreERT2:Ifngr1Flox, to systematically dissect the mechanisms underlying Xe-induced microglial state transitions, particularly its interaction with the IFNγ signaling pathway, providing a theoretical foundation for developing novel immune-modulating therapies.
Research Methods and Experiments
The research team developed a custom xenon inhalation apparatus to administer 30% Xe for 40 minutes per session to multiple AD mouse models. The effects of Xe on the microglial transcriptome were analyzed using flow cytometry, RNA-seq, and scRNA-seq to identify phenotypic changes. The impact of Xe on microglial phagocytic function was assessed in acute neurodegeneration models; Aβ plaque burden, neuritic dystrophy, and microglial activation were analyzed in APP/PS1 and 5xFAD mice; brain atrophy, behavioral performance, and astrogliosis were evaluated in P301S tau mice. Specific ablation of MGnD microglia was achieved using Clec7a-CreERT2;ROSA-DTRFlox mice to validate their role in pathology control. The necessity of IFNγ signaling in mediating Xe effects was investigated using Ifngr1-cKO mice and IFNγ neutralizing antibodies. Additionally, the regulatory effects of Xe on human microglia were validated in humanized 5xFAD-MITRG mice, and mechanistic validation was performed using an in vitro iMG culture system.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to systematically reveal the pleiotropic neuroprotective effects of xenon as a gaseous therapeutic in AD models. The core mechanism involves reprogramming microglia via IFNγ-dependent signaling to adopt an intermediate phenotype (pre-MGnD) that combines phagocytic activity with anti-inflammatory properties, thereby coordinately controlling Aβ deposition and tau pathology. This finding transcends the traditional dichotomy of microglial pro- versus anti-inflammatory states and introduces the novel concept of a 'functional intermediate state,' offering a fresh perspective on neuroimmune regulation for therapeutic development.
Xenon has an excellent safety profile and crosses the blood-brain barrier effectively, with a long history of clinical use in anesthesia, giving it high translational potential. This study provides robust preclinical data supporting clinical trials of Xe inhalation for AD. Future research should explore the therapeutic window of Xe at different AD stages, optimize dosing frequency and duration, and incorporate dynamic biomarker monitoring to assess immune modulation in humans. Moreover, small-molecule mimetics or enhancers targeting the IFNγ signaling pathway may represent a new direction for developing non-gaseous immunotherapies for AD.
Conclusion
This study systematically elucidates the therapeutic potential and immune mechanisms of inhaled xenon in mouse models of Alzheimer's disease. The findings demonstrate that Xe, by activating IFNγ signaling, induces microglia into an intermediate state ('pre-MGnD') that combines phagocytic function with anti-inflammatory properties, effectively enhancing Aβ plaque compaction, reducing neuritic dystrophy, mitigating brain atrophy, and improving behavioral deficits. These effects are validated across multiple Aβ and tau pathology models and show conservation in humanized mice. Notably, CD8+ T cells are identified as the primary source of IFNγ, and disruption of this pathway abolishes the protective effects of Xe, underscoring the critical role of neuro-immune crosstalk. Compared to current anti-Aβ antibody therapies, Xe—functioning as a broad-spectrum immune modulator—may intervene earlier in disease progression and offers superior safety and accessibility. These findings not only expand our understanding of neuroimmune regulation in AD but also provide strong experimental evidence for developing novel, non-invasive gaseous therapeutic strategies, holding significant translational value.
